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THE BIOLOGICAL MEANING OF ANTI-HBC POSITIVE RESULT IN BLOOD DONORS: RELATION TO
HBV-DNA AND TO OTHER SEROLOGICAL MARKERS
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SUMMARY
In order to assess the potential risk of anti-HBc-positive blood donors for post-transfusional hepatitis and to investigate whether
other HBV serological markers are capable of identifying the presence of the virus, 1000 first-time blood donors were enrolled
between June and July 1997. These donors were screened using routine Brazilian blood center tests (HIV 1 and 2, HTLV 1 and 2,
Chagas disease, Syphilis, HCV, HBsAg, anti-HBc and ALT ). The 120 (12%) found to be anti-HBc-positive underwent further tests:
HBe, anti-HBe, anti-HBs and HBV-DNA by PCR. Ten cases were HBsAg positive and all were HBV-DNA positive by PCR. Three
HBsAg-negative donors were HBV-DNA-positive. Two HBV-DNA-positive donors were also anti-HBs-positive. All the HBV-positive
donors had at least one HBV marker other than anti-HBc.
Anti-HBc is an important cause of blood rejection. Testing for HBsAg alone is not fully protective and anti-HBc remains necessary
as a screening test. The presence of anti-HBs is not always indicative of absence of the virus. The addition of other HBV serological
markers could represent an alternative in predicting the presence of the virus when compared with PCR. It is recommended that other
studies should be carried out to confirm this finding.
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INTRODUCTION
Blood supply is a major concern all over the world. In Brazil, the
introduction of Hepatitis B core antibody (anti-HBc) as a surrogate marker
for HIV and viral hepatitis in blood transfusion centers has lead to a
high donation rejection rate. This rate varies widely over the country, in
the Amazonian area as much as 43.7% being discarded (CLEMENS et
al., 2000).
Some studies have been carried out in Brazil with different and,
sometimes, contradictory results.
The residual transfusion risk for hepatitis B and C in Santa Catarina
(Brazil) has decreased in the 1990’s, after the introduction of anti-HBc
and anti-HCV in the screening routine (KUPEK, 2001). A recent study
shows a high prevalence of anti-HBc (16%) in blood donors, but no
HBV-DNA was detected among them (ALMEIDA NETO et al., 2001).
MARTELLI et al. (1999) pointed out that there is not enough evidence
to discontinue anti-HBc screening in Brazil.
The significance of anti-HBc in the absence of the surface antigen is
somewhat controversial. Such finding could represent 1) a situation where
despite anti-HBs and anti-HBe being undetectable, the patient is
immunized; 2) a case where HBsAg levels are very low to be detected
with routine assays; 3) false-positivity or cross-reactivity of anti-HBc;
and 4) an immunological window period, in which HBsAg is already
undetectable and the surface antibody is not yet detectable (KLEINMAN
et al., 1997). In the first three situations no conclusion can be drawn
concerning the presence or absence of HBV without referring to
molecular biology methods (BONINO et al., 1981).
Molecular methods have demonstrated the presence of the virus in
patients with anti-HBc alone with a frequency varying from 0 to 90%
(LUO et al., 1991; SHIH et al., 1990; WANG et al., 1991). In Brazil,
HBV-DNA positivity ranges from 0.8% among blood donors to 23.4%
among individuals attending outpatient clinics in the state of São Paulo
(SUCUPIRA, 1997; CRUZ, 1997). Such wide discrepancy, not
completely understood, could result from virological, immunological,
or methodological factors, besides region HBV endemicity.
In Northeast Brazil, the high prevalence of anti-HBc-positive blood
donors has resulted in a very high level of donation rejection, with obvious
consequences in the setting of blood scarcity, and very high costs. On
the other hand, with the serological markers used in Brazilian blood
transfusion centers, one could not assure the safety of a blood transfusion
from anti-HBc-positive donor.
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The main objective of this study was to assess how frequent is the
detection of HBV-DNA among blood donors with normal ALT levels
and with negative test results for all safety markers routinely used in
Brazilian transfusion centers (syphilis, Chagas disease, HIV, HTLV I/II,
HBsAg and HCV) but anti-HBc.
MATERIAL AND METHODS
Study population: Between June and July 1997, 1000 first time
blood donors at the City of Recife (Northeast of Brazil) blood transfusion
center were ascertained in a cross-sectional study. Among donors, the
frequency of anti-HBc-positive was calculated and its concomitance with
HBV-DNA investigated.
Furthermore, among these anti-HBc-positive individuals, it was
determined whether other HBV serological markers, not routinely used
in Brazilian transfusion centers (anti-HBs, anti-HBe, HBe), could be
safely used as surrogate markers to predict the presence of HBV-DNA.
Data Collection: For each participant in the study, the following
data were obtained: 1) gender, age, schooling and donation model; 2)
history of jaundice or hepatitis, sexual habits, arterial hypertension or
hypotension, medication in use, recent alcohol intake, body mass index,
symptoms and signals suggesting Dengue Fever or anaemia and skin
lesions.
According to these latter variables, the donor was included in or
excluded from the study. From the donors included, three samples were
collected, two for routine blood transfusion center screening tests and
one for centrifugation and freezing at –22o C. In this last group, when
the sample was positive for anti-HBc, serological markers not routinely
used (anti-HBe, anti-HBs and HBeAg) and a PCR for HBV-DNA were
performed.
Prior to inclusion standard written informed consent was obtained
from all participants and the study was approved by the Ethics Committee
of HEMOPE (Hemocentro de Pernambuco).
Laboratory Studies: The samples were tested in accordance to the
Brazilian Health Ministry recommendations for blood transfusion centers.
One thousand samples were tested for Chagas Disease, HCV, HBV
(HBsAg and anti-HBc), HIV 1 and 2, HTLV 1 and 2, and syphilis
(VDRL).
The first 660 samples were tested for these infections using ELISA
methodology (ORGANON). The last 334 samples were tested using
chemoluminescense methodology (ABBOTT), with the exception of
Chagas Disease testing which was performed using ELISA methods
(ABBOTT). Non-routine HBV serological tests were performed on the
anti-HBc positive samples as follows: anti-HBs (ELISA, SANOFI-
PASTEUR), HBe and anti-HBe (Microparticle Enzyme Immunoassay
ABBOTT). In the anti-HBC-positive samples, HBV-DNA PCR tests were
performed using the Multiple Primers Induced Overlapping Amplification
Assay (MUPROVAMA) as described (LU et al., 1999).
Anti-HBc positive samples were tested for PCR and for HBeAg,
anti-HBe and anti-HBs.
RESULTS
Among the 1000 blood donors, there were 120 anti-HBc-positive
(12%). Three samples were lost and could not, for that reason, be tested
for non routine tests, i.e., HBeAg, anti-HBe and anti-HBs remaining
117 anti-HBC positive patients. Male and less educated blood donors
were the great majority. Some characteristics of the serologic profile of
the 117 anti-HBc positive donors are shown on Table 1.
Among the 120 anti-HBc-positive blood donors, 13 were HBV-DNA
positive, including 10 HBsAg positive and three HBsAg negative,
showing the infectivity of three HBsAg-negative donors.
All the 10 HBsAg-positive donors were anti-HBs-negative and HBV-
DNA-positive. However, two anti-HBs-positive donors were also HBV-
DNA-positive, indicating that the protective effect of this antibody was
not always present.
Performing non-routine blood transfusion center HBV tests in all
120 anti-HBc positive blood donors, it was found that all 13 HBV-DNA-
positive donors were also positive for at least another HBV marker (either
HBsAg, or anti-HBs, or HBeAg, or anti-HBe). Ten among them were
already known as HBsAg positive by tests performed during the
serological routine screening. Three HBsAg negative and HBV-DNA
positive blood donors were not only anti-HBc positive. Two of them
were anti-HBs positive and one was anti-HBe positive. There was no
case of anti-HBc positive who was also HBV-DNA-positive without
another positive serological test. Eighty-four HBV-DNA-negative donors
displayed at least another HBV marker and among 20 HBV-DNA-
negative donors, all HBV markers but anti-HBc, were negative.
DISCUSSION
This study showed insufficient effectiveness of HBsAg screening
for protecting blood recipients from HBV infection. Three HBsAg-
negative blood donors were HBV-DNA-positive and if it were not for
the screening of anti-HBc recipients would have been infected. These
findings have been broadly supported by previous studies (CARLONI
et al., 1986; LEON et al., 1999). On the other hand, in our study detection
of anti-HBs did not rule out presence of the virus.
Table 1
Comparison between results of serological markers for hepatitis B virus
and PCR in individuals anti-HBc positive at Recife Blood
Transfusion Center in 1997
PCR HBsAg Anti-HBs Markers*
(-) (+) (-) (+) (-) (+)
(+) 10 3 2 11 13 076.9% 23.1% 15.4% 84.6% 100% 0%
(-) 0 107 73 31 84 200% 100% 70.2% 29.8% 80.8% 19.2%
From: HEMOPE; *The presence of at least one of the following serologic
markers: HBsAg, anti-HBs, HBeAg, anti-HBe.
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Anti-HBs, as a marker of recovery from HBV infection and protective
immunity, is generally believed to be so strong that COELHO &
NOGUEIRA (1995) claimed that it would be safe to release anti-HBc
and anti-HBs-positive blood donations. However, in this study, two anti-
HBs-positive donors were also HBV-DNA-positive. This apparent
paradoxical immuno-virological pattern might be due to the presence of
HBV quasi-species, often responsible for unusual serological patterns
(BLUM, 1993). It did not seem to be the case in this study. The surface
genes of samples from the two unusual cases were sequenced and revealed
genotype F (common in South America) and genotype A (common in
Europe). No mutations that would account for the failure of surface
antigen detection was found (TONG, 2001). If the absence of HBsAg
does not always indicate the absence of the virus and anti-HBs
seropositivity does not always indicate its presence, one could conclude
that relying entirely on the serological pattern to rule in or out the virus
might be risky.
This phenomenon could be ascribed to limitations of the screening
test in terms of specificity and sensibility, to an as yet incomplete
knowledge of HBV pathogenesis, or to its wide genetic variation
(HARRISSON, 1996). In anti-HBs positive subjects it has been claimed
that the virus is totally cleared by both cellular and humoral immunity.
Of interest, not a single HBV-DNA-positive case was solely anti-HBc-
positive.
Our study offers strong support to the maintenance of anti-HBc, in
order to minimize the chances of post-transfusion HBV infection.
However, the introduction of other HBV markers in blood transfusion
centers should be considered as an alternative to reducing the possible
excessive disposal of blood bags in Brazilian blood banks, possibly due
to a great quantity of false-positive results. In this study no solely anti-
HBc-positive blood donor was HBV-positive when assessed by HBV-
DNA PCR. All HBV PCR positive blood donors were positive also to at
least another HBV serological marker.
In conclusion, this study offers some evidence that the presence of
two HBV serologic markers may be an indication of a positive HBV
PCR. Nonetheless, larger studies are warranted including individuals
from different groups, mainly subjects who are HBV PCR negative,
together with patients with positive seromarkers, and the PCR and anti-
HBs positive subjects before defining new strategies for blood transfusion
safety policies based on these findings.
RESUMO
Significado biológico do resultado anti-HBc positivo em
doadores de sangue: relação com HBV-DNA e outros
marcadores sorológicos
Para verificar o risco potencial para hepatite viral pós-transfusional
de doadores anti-HBc positivos e investigar se outros marcadores
sorológicos do HBV poderiam identificar a presença ou não do vírus,
mil doadores de primeira vez foram recrutados entre junho e julho de
1997. Estes doadores foram testados para os testes de rotina utilizados
em centros de transfusão brasileiros. Cento e vinte desses doadores foram
anti-HBc positivos (12%). Nestes foram realizados os testes HbeAg,
anti-HBc, anti-HBs e a pesquisa do HBV-DNA por PCR.
Dez eram HbsAg positivos, todos com presença do HBV-DNA
demonstrada por PCR. Três doadores HbsAg negativos foram HBV-
DNA positivos.
Dois doadores HBV-DNA positivos também o foram para o anti-
HBs. Todos os doadores HBV positivos apresentavam pelo menos outro
marcador sorológico do HBV, além do anti-HBc.
O anti-HBc é uma importante causa de descarte de sangue. A pesquisa
isolada do HbsAg não é completamente protetora e a presença do anti-
HBc permanece necessária como teste de triagem.
A presença do anti-HBs não é sempre indicativa da ausência do vírus.
A adição de outros marcadores pode ser uma alternativa para predizer
a presnça do vírus quando comparada com a PCR. Outros estudos, no
entanto, devem ser conduzidos para confirmar este achado.
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